BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Feb 8, 2016
Clinical News

Padeliporfin di-potassium: Phase III data

...81 low- and intermediate-risk prostate cancer patients showed that a single infusion of 4 mg/kg Tookad...
...Last month, Steba submitted an MAA to EMA for Tookad to treat localized prostate cancer. Tookad...
...to treat low-risk localized prostate cancer. Steba Biotech Ltd. , Luxembourg, Luxembourg Product: Padeliporfin di-potassium ( Tookad...
BioCentury | Feb 1, 2016
Clinical News

Padeliporfin di-potassium regulatory update

...Steba submitted an MAA to EMA for Tookad padeliporfin di-potassium to treat localized prostate cancer. The product...
...a photosensitizer derived from palladium-substituted bacteriochlorophyll. Steba Biotech Ltd. , Luxembourg, Luxembourg Product: Padeliporfin di-potassium ( Tookad...
Items per page:
1 - 3 of 3